Evangelos N Liberopoulos

List of Publications by Year
in descending order

109	3,574	201385 27	143772 57
papers	citations	h-index	g-index

109	109	109	4804
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism: Clinical and Experimental, 2006, 55, 1293-1301.	1.5	236
2	Diabetes mellitus and electrolyte disorders. World Journal of Clinical Cases, 2014, 2, 488.	0.3	213
3	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	1.5	208
4	“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. Current Vascular Pharmacology, 2011, 9, 533-571.	0.8	187
5	Multiple actions of high-density lipoprotein. Current Opinion in Cardiology, 2008, 23, 370-378.	0.8	180
6	Spurious Electrolyte Disorders: A Diagnostic Challenge for Clinicians. American Journal of Nephrology, 2013, 38, 50-57.	1.4	165
7	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.4	163
8	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrology Dialysis Transplantation, 2006, 22, 118-127.	0.4	158
9	Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015, 243, 257-259.	0.4	148
10	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	6.3	142
11	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. Angiology, 2007, 58, 689-697.	0.8	133
12	“European Panel On Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Current Vascular Pharmacology, 2011, 9, 531-532.	0.8	110
13	Novel roles of vitamin D in disease: What is new in 2011?. European Journal of Internal Medicine, 2011, 22, 355-362.	1.0	90
14	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
15	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opinion on Drug Safety, 2008, 7, 717-725.	1.0	63
16	Lipid testing in infectious diseases: possible role in diagnosis and prognosis. Infection, 2017, 45, 575-588.	2.3	45
17	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study. Clinical Therapeutics, 2010, 32, 492-505.	1.1	43
18	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones, 2018, 17, 333-350.	0.9	43

#	Article	IF	Citations
19	COVID-19 and diabetes: What does the clinician need to know?. Primary Care Diabetes, 2020, 14, 558-563.	0.9	38
20	Statin therapy with or without ezetimibe and the progression to diabetes. Journal of Clinical Lipidology, 2016, 10, 306-313.	0.6	37
21	Vitamin D and Metabolic Syndrome: Is There a Link?. Current Pharmaceutical Design, 2010, 16, 3417-3434.	0.9	36
22	Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. Rheumatology, 2021, 60, 5527-5537.	0.9	36
23	Statin Pleiotropy Against Renal Injury. Journal of the Cardiometabolic Syndrome, 2009, 4, E4-9.	1.7	35
24	Safety Evaluation of Î±-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants, 2020, 9, 1011.	2.2	33
25	Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis. Nutrients, 2020, 12, 2436.	1.7	31
26	Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 29-41.	1.4	30
27	Autoimmune manifestations in patients with visceral leishmaniasis. Journal of Microbiology, Immunology and Infection, 2013, 46, 302-305.	1.5	29
28	Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review. Journal of Cardiovascular Development and Disease, 2021, 8, 18.	0.8	29
29	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones, 2016, 15, 8-14.	0.9	28
30	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. Angiology, 2012, 63, 358-366.	0.8	27
31	Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic. Angiology, 2015, 66, 346-353.	0.8	27
32	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Atherosclerosis, 2018, 277, 308-313.	0.4	26
33	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Current Medical Research and Opinion, 2015, 31, 221-228.	0.9	25
34	Uric acid and incident chronic kidney disease in dyslipidemic individuals. Current Medical Research and Opinion, 2018, 34, 1193-1199.	0.9	25
35	Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?. Medical Hypotheses, 2021, 146, 110452.	0.8	25
36	Hypocholesterolemia. Current Vascular Pharmacology, 2011, 9, 200-212.	0.8	24

#	Article	IF	Citations
37	Leptospirosis is Associated with Markedly Increased Triglycerides and Small Dense Lowâ€Density Lipoprotein and Decreased Highâ€Density Lipoprotein. Lipids, 2011, 46, 953-960.	0.7	24
38	The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Archives of Medical Science, 2012, 3, 437-443.	0.4	23
39	High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. Atherosclerosis, 2016, 247, 58-63.	0.4	21
40	The CHADS 2 and CHA 2 DS 2 -VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels. International Journal of Cardiology, 2017, 241, 194-199.	0.8	20
41	Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 229-233.	1.0	19
42	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. International Journal of Cardiology, 2021, 345, 119-124.	0.8	19
43	Cryoglobulinemic purpura in visceral leishmaniasis. Rheumatology International, 2005, 25, 469-471.	1.5	18
44	Effect of Rosuvastatin Monotherapy and in Combination With Fenofibrate or Omega-3 Fatty Acids on Serum Vitamin D Levels. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 382-386.	1.0	18
45	Visceral leishmaniasis is associated with marked changes in serum lipid profile. European Journal of Clinical Investigation, 2014, 44, 719-727.	1.7	18
46	No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study. Archives of Medical Sciences Atherosclerotic Diseases, 2017, 2, 52-60.	0.5	18
47	Should a statin be prescribed to every patient with heart failure?. Heart Failure Reviews, 2008, 13, 211-225.	1.7	17
48	Prevalence and Risk Distribution of Residual Dyslipidemia in Statin-Treated Patients in Greece. Angiology, 2012, 63, 184-193.	0.8	17
49	Effects of increased body weight and short-term weight loss on serum PCSK9 levels â€“ a prospective pilot study. Archives of Medical Sciences Atherosclerotic Diseases, 2017, 2, 46-51.	0.5	17
50	Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. Journal of Cardiology, 2019, 74, 290-295.	0.8	16
51	PCSK9 inhibitors in clinical practice: Novel directions and new experiences. Hellenic Journal of Cardiology, 2020, 61, 241-245.	0.4	16
52	Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications. Current Medicinal Chemistry, 2018, 25, 1549-1566.	1.2	16
53	Effect of Switch to the Highest Dose of Rosuvastatin Versus Addâ€onâ€Statin Fenofibrate Versus Addâ€onâ€Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia. Cardiovascular Therapeutics, 2014, 32, 139-146.	1.1	15
54	Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake. JACC: Cardiovascular Imaging, 2019, 12, 2573-2574.	2.3	15

#	Article	IF	Citations
55	Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2020, 27, 157-165.	0.8	14
56	Canagliflozin and Amputation Risk: Evidence So Far. International Journal of Lower Extremity Wounds, 2020, 19, 21-26.	0.6	14
57	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European Journal of Clinical Investigation, 2013, 43, 698-707.	1.7	12
58	The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-Î³ activating capacity on plasma 8-isoprostane prostaglandin F 2a levels. Archives of Medical Science, 2013, 1, 172-176.	0.4	12
59	Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: AÂpilot randomized study. Clinical Nutrition ESPEN, 2019, 29, 198-202.	0.5	12
60	Effects of Eprosartan on Serum Metabolic Parameters in Patients with Essential Hypertension. Open Cardiovascular Medicine Journal, 2007, 1, 22-26.	0.6	11
61	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. International Journal of Stroke, 2021, 16, 738-750.	2.9	11
62	Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. Atherosclerosis, 2020, 309, 67-69.	0.4	11
63	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Hormones, 2017, 16, 306-312.	0.9	9
64	Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. Case Reports in Endocrinology, 2019, 2019, 1-4.	0.2	9
65	Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity â€“ the effect of vitamin D supplementation: a pilot study. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 64-71.	0.5	9
66	Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery. European Journal of Preventive Cardiology, 2021, 28, 813-815.	0.8	9
67	Oxidized phospholipids and lipoprotein(a): An update. European Journal of Clinical Investigation, 2022, 52, e13710.	1.7	9
68	Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II. Archives of Medical Science, 2019, 15, 821-831.	0.4	8
69	Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105708.	0.7	8
70	Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic. Quality of Life Research, 2022, 31, 193-204.	1.5	8
71	New-onset extremely low levels of high-density lipoprotein cholesterol. Journal of Clinical Lipidology, 2012, 6, 593-595.	0.6	7
72	Effects of Manidipine Plus Rosuvastatin Versus Olmesartan Plus Rosuvastatin on Markers of Insulin Resistance in Patients With Impaired Fasting Glucose, Hypertension, and Mixed Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 113-118.	1.0	7

#	Article	IF	Citations
73	Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARÎ³-Activating Capacity. Angiology, 2015, 66, 36-42.	0.8	7
74	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones, 2016, 15, 8-14.	0.9	7
75	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. Lipids in Health and Disease, 2020, 19, 114.	1.2	6
76	Metabolically healthy obesity and risk of incident type 2 diabetes in 1077 statin-treated individuals: A six-year retrospective study. European Journal of Preventive Cardiology, 2020, 27, 2341-2344.	0.8	6
77	Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety, 2022, 21, 291-293.	1.0	6
78	Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-Î³ Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A₂. Metabolic Syndrome and Related Disorders, 2011, 9, 217-223.	0.5	5
79	A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study. International Journal of Cardiology, 2016, 217, 183-189.	0.8	5
80	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. Journal of Clinical Lipidology, 2018, 12, 826-829.	0.6	5
81	Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries. Current Pharmaceutical Design, 2019, 24, 3605-3615.	0.9	5
82	Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. Journal of Cardiovascular Pharmacology, 2021, 78, e12-e19.	0.8	5
83	Anakinra in COVID-19: A step closer to the cure. European Journal of Internal Medicine, 2022, 96, 113-114.	1.0	5
84	Comparison of Hemoglobin A_{1c} and Fasting Glucose Criteria to Diagnose Diabetes Among People With Metabolic Syndrome and Fasting Glucose Above 100â€ƒmg/dL (5.5â€ƒmmol/L). Journal of Clinical Hypertension, 2010, 12, 543-548.	1.0	4
85	No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study. Archives of Medical Sciences Atherosclerotic Diseases, 2019, 4, 162-166.	0.5	4
86	Attainment of multifactorial treatment targets among the elderly in a lipid clinic. Journal of Geriatric Cardiology, 2015, 12, 239-45.	0.2	4
87	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Endocrine, 2022, 76, 324-330.	1.1	4
88	A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2022, 22, 357-361.	1.0	4
89	No association between high-density lipoprotein levels and ventricular repolarization indexes in subjects with primary hypercholesterolemia. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 53-58.	0.6	3
90	No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome. Journal of Nutrition & Intermediary Metabolism, 2019, 16, 100093.	1.7	3

#	Article	IF	Citations
91	A patient with new-onset hypercholesterolemia. Journal of Clinical Lipidology, 2009, 3, 143-145.	0.6	2
92	Lipidâ€Modulating Treatments for Mixed Dyslipidemia Increase HDLâ€Associated Phospholipase A₂ Activity with Differential Effects on HDL Subfractions. Lipids, 2013, 48, 957-965.	0.7	2
93	Correlation between the CHADS2, CHA2DS2-VASC scores and the incidence of cardiovascular disease in individuals without atrial fibrilation and their comparison with hellenic score and ASCVD risk. Atherosclerosis, 2017, 263, e173.	0.4	2
94	Low high-density lipoprotein cholesterol levels improve the performance of the CHADS2 and CHA2DS2-VASc scores for the prediction of new-onset atrial fibrillation. International Journal of Cardiology, 2017, 247, 18.	0.8	2
95	Bridging the treatment gap in patients at â€˜extremeâ€™ cardiovascular risk: Evidence from a lipid clinic. Atherosclerosis, 2019, 281, 216-218.	0.4	2
96	Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience. Archives of Medical Research, 2021, 52, 397-404.	1.5	2
97	Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. Diabetology International, 2022, 13, 325-329.	0.7	2
98	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). Hormones, 2017, 13, 200-204.	0.9	2
99	Lipoprotein apheresis: a Hellenic consensus on its clinical use. Hellenic Journal of Cardiology, 2021, 62, 460-462.	0.4	2
100	Statin escape phenomenon: Fact or fiction?. World Journal of Experimental Medicine, 2017, 7, 25.	0.9	1
101	Incidence of diabetes according to metabolic and weight status in postmenopausal women treated with statins: a 6-year study. Menopause, 2020, 27, 1196.	0.8	1
102	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. Current Pharmaceutical Design, 2021, 27, 2537-2544.	0.9	1
103	Metabolic markers to predict incident diabetes in statin-treated individuals. Atherosclerosis, 2017, 263, e259.	0.4	0
104	The CHADS2 and CHA2DS2-VASC scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels. Atherosclerosis, 2017, 263, e173.	0.4	0
105	Uric acid levels and risk of incident chronic kidney disease. Atherosclerosis, 2017, 263, e271.	0.4	0
106	Is Mesenteric Panniculitis a Sign for Autoimmune Diabetes in Adults?. AACE Clinical Case Reports, 2019, 5, e181-e183.	0.4	0
107	Authorâ€™s Reply. Journal of Cardiology, 2020, 75, 217.	0.8	0
108	Authorsâ€™ Reply to: Do All Gliflozins Reduce Stroke in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function?. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105810.	0.7	0

#	Article	IF	Citations
109	Bradycardia and coronavirus disease 2019: What is behind?. Clinical Cardiology, 2021, 44, 1187-1187.	0.7	0